CAS 313489-71-3

Formel: C27H33N5O2

InChl: InChI=1S/C27H33N5O2/c1-30-13-10-23(11-14-30)31-15-17-32(18-16-31)27(34)25(21-5-3-2-4-6-21)29-26(33)22-8-7-20-9-12-28-24(20)19-22/h2-9,12,19,23,25,28H,10-11,13-18H2,1H3,(H,29,33)/t25-/m1/s1

InChI Key: VYNKVNDKAOGAAQ-RUZDIDTESA-N

SMILES: CN1CCC(CC1)N2CCN(CC2)C(=O)[C@@H](C3=CC=CC=C3)NC(=O)C4=CC5=C(C=C4)C=CN5

LY 517717

CAS: 313489-71-3

LY 517717

Formel: C₂₇H₃₃N₅O₂

Reinheit: 99.5%

Molekulargewicht: 459.58

Ref: 54-BUP07644

LY 517717

CAS: 313489-71-3

Ref: IN-DA00C98U

LY 517717

Kontrolliertes Produkt

CAS: 313489-71-3

Formel: C₂₇H₃₃N₅O₂

Farbe und Form: Neat

Molekulargewicht: 459.583

Ref: TR-L486750

LY 517717

CAS: 313489-71-3

LY 517717 is an orally active inhibitor of coagulation factor Xa with antithrombotic activity for the study of venous thromboembolism (VTE).

Formel: C₂₇H₃₃N₅O₂

Reinheit: 99.30% - 99.88%

Farbe und Form: Solid

Molekulargewicht: 459.58

Ref: TM-T27920

LY 517717

CAS: 313489-71-3

LY 517717 is an oral, investigational anticoagulant that is being studied as a potential treatment for acute coronary syndrome (ACS). It acts by inhibiting the prothrombinase complex and the activated partial thromboplastin time (APTT). LY 517717 has been shown to be safe and well tolerated in clinical trials. It has also been shown to have a favorable safety profile with no major adverse events or bleeding complications. LY 517717 is currently in clinical development as a potential anticoagulant therapy for ACS.

Formel: C₂₇H₃₃N₅O₂

Reinheit: Min. 95%

Molekulargewicht: 459.6 g/mol

Ref: 3D-NMA48971